Drug Profile
Anti-TSHR CAR T cell therapy - Innovative Cellular Therapeutics
Alternative Names: Anti-thyroid stimulating hormone receptor chimeric antigen receptor T cell therapy - Innovative Cellular Therapeutics; TSHR CART cell - Innovative Cellular Therapeutics; TSHR CART targeted therapy - Innovative Cellular TherapeuticsLatest Information Update: 25 Feb 2022
Price :
$50
*
At a glance
- Originator Innovative Cellular Therapeutics
- Class CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Thyroid cancer
Most Recent Events
- 25 Feb 2022 Phase-I/II development is ongoing in Thyroid cancer (Second-line therapy or greater) in China (Parenteral) (Innovative Cellular Therapeutics pipeline, February 2022)
- 10 Apr 2021 Efficacy data from a clinical trial in Thyroid cancer presented at the 112th Annual Meeting of the American Association for Cancer Research (AACR-2021)
- 28 Jun 2018 Innovative Cellular Therapeutics initiates enrolment in a phase I trial for Thyroid cancer (Second-line therapy or greater) in China (ChiCTR1800017612)